QT Dispersion in Patients With Systemic Lupus Erythematosus (SLE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

124 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

QT dispersion can be a useful, simple noninvasive method for the early detection of cardiac involvement in SLE patients with active disease. The investigators therefore recommend cardiovascular evaluation for every SLE patient with an SLEDAI higher than 10.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus

NCT03179046

Systemic Lupus Erythematosus

COMPLETED

Systemic Lupus Erythematous and Heart Conduction Disorders

NCT02162992

Lupus Erythematosus, Systemic Atrioventricular Block Sudden Death

COMPLETED

Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

NCT03122431

Systemic Lupus Erythematosus (SLE) Juvenile SLE Cutaneous Lupus

COMPLETED PHASE4

Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease

NCT00188188

Systemic Lupus Erythematosus

UNKNOWN PHASE4

Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus

NCT04580108

Systemic Lupus Erythematosus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: Patients with systemic lupus erythematosus (SLE) have increased cardiovascular morbidity and mortality. Although autopsy studies have documented that the heart is affected in most SLE patients, clinical manifestations occur in less than 10%. QT dispersion is a new parameter that can be used to assess homogeneity of cardiac repolarization and autonomic function. We compared the increase in QT dispersion in SLE patients with high disease activity and mild or moderate disease activity.

Methods: One hundred twenty-four patients with SLE were enrolled in the study. Complete history and physical exam, ECG, echocardiography, exercise test and SLE disease activity index (SLEDAI) were recorded. Twenty patients were excluded on the basis of our exclusion criteria. The patients were divided to two groups based on SLEDAI: 54 in the high-score group (SLEDAI \>10) and 50 in the low-score group (SLEDAI \<10).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SLE

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High SLEDAS

High SLE disease activity score

No interventions assigned to this group

Low SLEDAS

SLE patient with low score

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* no administration of drugs that would potentially influence QT duration except hydroxychloroquine
* no history of ischemic heart disease, congestive heart failure, atrial fibrillation, bundle branch block or abnormal serum electrolytes
* normal resting ECG and a good-quality ECG recording to measure the QT interval.

Exclusion Criteria

* moderate or severe valve disease
* atrial fibrillation and other ECG abnormalities
* systolic left ventricular dysfunction (ejection fraction \<50% or left ventricular end diastolic dimension \>5.5 mm
* unreliable identification of the end of the T wave in the ECG and
* known presence of cardiac disease including hypertension, diabetes or coronary artery disease.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No